RNAZ — Transcode Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1829635 ·
Last close
$1.71
Market Cap
$1.81M
52W High
$15.94
52W Low
$1.52
ADV30
73,198
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,208,728 | -6,750,128 | 151,010,103 | 8,383,393 | 12,651,920 |
| Mar 2026 | 0 | — | -17,615,194 | -17,785,071 | 157,164,882 | 12,835,454 | 12,643,694 |
| Dec 2025 | 0 | — | -6,485,234 | -13,443,110 | 162,398,689 | 17,813,521 | 152,063,223 |
| Sep 2025 | 0 | — | -4,539,026 | -4,856,051 | 5,226,682 | 2,835,916 | 3,800,703 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,397,589
Investing CF
$-4,436
Financing CF
$22,668,325
CapEx
$-500
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-102.39
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-115,648,063
Inventory
—
Receivables
$638
ST Investments
—
EBIT TTM
$-39,896,855
Pretax Income TTM
$-39,903,357
Interest Exp TTM
$6,502
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -17,915,044 | -34,661,076 | 162,398,689 | 10,518,687 | 151,880,002 | -19,516,229 |
| Dec 2024 | 0 | -15,136,633 | -16,754,971 | 7,294,499 | 9,313,233 | -2,018,734 | -13,335,947 |
| Dec 2023 | 0 | -18,495,481 | -18,546,095 | 5,169,701 | 3,528,887 | 1,640,814 | -18,074,535 |
| Dec 2022 | 0 | -17,553,392 | -17,564,968 | 7,587,986 | 4,347,290 | 3,240,696 | -15,762,512 |
TTM Snapshot
Revenues TTM
$170,940
NetIncome TTM
$-40,360,734
OpCashFlow TTM
—
Assets (Latest)
$157,164,882
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARTL | ARTELO BIOSCIENCES, INC. | $1.85M | $3.37 | — |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $1.88M | $0.79 | — |
| AGNPF | Grey Matters Health Inc. | $1.70M | $0.31 | — |
| VBIO | Valion Bio, Inc. | $1.96M | $2.21 | — |
| SBFM | Sunshine Biopharma Inc. | $1.67M | $0.43 | — |
News headlines (Yahoo Finance, 1h cache)
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
2026-09-22 12:04 · Yahoo
Join Today's Live Investor Webinar with TransCode Therapeutics
2026-09-16 13:00 · Yahoo
TransCode Therapeutics Announces Leadership Transition
2026-09-10 20:10 · Yahoo
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
2026-09-03 13:00 · Yahoo
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-08-07 13:00 · Yahoo
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
2026-06-08 12:04 · Yahoo
RNAZ: Introducing RNA Therapeutics
2026-06-08 09:27 · Yahoo
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
2026-06-03 11:41 · Yahoo
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
2026-06-03 12:04 · Yahoo
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
2026-04-07 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.